Neotaxan (Paclitaxel)

Paclitaxel, the active ingredient in Neotaxan, is a taxane presented as an intravenous formulation for intravenous use. It is employed in the treatment of several solid tumours, including breast, ovarian, non‑small cell lung cancer and Kaposi sarcoma, and is administered under the supervision of an oncologist.

GNH USA supplies Neotaxan as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide, ensuring quality and regulatory compliance.

Neotaxan (paclitaxel) is a taxane chemotherapy used for solid tumours that rely on microtubule dynamics. - Breast cancer: improves progression‑free and overall survival when combined with standard regimens. - Ovarian cancer: enhances response rates in first‑line and recurrent settings. - Non‑small cell lung cancer: provides disease control as part of combination therapy. - Kaposi sarcoma: reduces lesion burden and disease progression in advanced cases.

Paclitaxel is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Alopecia: hair loss that is usually reversible after treatment. - Peripheral neuropathy: tingling or numbness in extremities. - Fatigue: generalized tiredness affecting daily activities. - Nausea and vomiting: gastrointestinal upset common with chemotherapy. - Myalgia: muscle pain or cramps.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: including anaphylaxis during infusion. - Febrile neutropenia: fever with low neutrophil count requiring urgent care. - Cardiac arrhythmias: irregular heart rhythms observed during infusion. - Severe peripheral neuropathy: may become permanent. - Pulmonary toxicity: rare interstitial lung disease. - Hepatotoxicity: significant liver enzyme elevations.

Use of Neotaxan requires careful monitoring and patient assessment before and during therapy. - Blood count monitoring: perform complete blood counts before each cycle to detect neutropenia. - Cardiac evaluation: assess baseline ECG and monitor for arrhythmias during infusion. - Hypersensitivity risk: pre‑medicate with corticosteroids and antihistamines to reduce infusion reactions. - Liver function: avoid in patients with severe hepatic impairment; adjust dose if needed. - Contraception: advise both male and female patients of reproductive potential to use effective contraception during treatment and for a defined period after. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Paclitaxel may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP2C8 inhibitors (e.g., gemfibrozil): increase paclitaxel exposure and toxicity. - Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): raise plasma concentrations, heightening adverse effects. - Concurrent myelosuppressive agents: compound bone‑marrow suppression, raising infection risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce paclitaxel levels, potentially decreasing efficacy. - Anticoagulants (e.g., warfarin, DOACs): may increase bleeding tendency. - Corticosteroids: can mitigate hypersensitivity but may also affect immune response.